Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges

Allahdadi, Kyan James; Tostes, Rita C.; Webb, R.

doi:10.2174/187152509789541882

Cited by 80 publications

(46 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 Sildenafil citrate is effective in female sexual function, particularly sexual arousal. 19 Its effects on sexual arousal, lubrication, 31 and relaxation of smooth muscles especially in vaginal arteries, veins, and capillaries, and clitoris have also been mentioned in other studies. 32 Nevertheless, some researchers believe that the complete role of this mechanism in vaginal congestion as a response to sexual arousal is still unknown.…”

mentioning

confidence: 80%

Comparison of the Effects of Elaeagnus angustifolia Flower Capsule and Sildenafil Citrate Tablet on Anxiety Resulting From Sexual Dysfunction in Women Referring to the Selected Clinics of Shiraz University of Medical Sciences

Zeinalzadeh

Akbarzadeh

Mohagheghzadeh

et al. 2015

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

Dissatisfaction from sexual relationships can result in deprivation as well as problems, such as depression, anxiety, and destruction of family's mental health. One hundred twenty-five women (18 to 40 years) who suffered from hypoactive sexual desire disorder were divided into Elaeagnus angustifolia flower (4.5 g g daily for 35 days), sildenafil citrate tablet (50 mg for 4 weeks), and control groups. The study data were collected using the Female Sexual Function Index and Spielberger's questionnaire and measurement of thyroid-stimulating hormone and prolactin hormone. In the Elaeagnus angustifolia group, the mean score of state and trait anxiety decreased after the intervention. In the sildenafil citrate group also, the mean score of state anxiety decreased from 22.15 + 4.98 to 20.1 + 5.15 (P ¼ .001) and that of trait anxiety decreased from 23.07 + 4.44 to 21.55 + 4.82 (P ¼ .002) after the intervention. Consumption of sildenafil citrate tablet was effective in reduction of the mean score of anxiety resulting from sexual dysfunction.

show abstract

mentioning

confidence: 80%

Comparison of the Effects of Elaeagnus angustifolia Flower Capsule and Sildenafil Citrate Tablet on Anxiety Resulting From Sexual Dysfunction in Women Referring to the Selected Clinics of Shiraz University of Medical Sciences

Zeinalzadeh

Akbarzadeh

Mohagheghzadeh

et al. 2015

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

show abstract

“…For a successful programme, the right contraction has to be confirmed and recorded before the training, and the participants are monitored and supported to continue with the programme [7,13]. There is an overall widespread endorsement among the selected studies that PFMT should be integrated into the first line conservative management programmes for women with urinary incontinence.…”

Section: Implications For Practicementioning

confidence: 99%

“…SUI occurs when intra-vesical pressure exceeds urethral closure pressure in the absence of a detrusor contraction. SUI may be due to bladder neck hyper-mobility or poor urethral closure pressure [7]. The pelvic floor muscles (PFM) function to elevate the bladder, preventing descent of the bladder neck during rises in intra-abdominal pressure and to occlude the urethra.…”

Section: Introductionmentioning

confidence: 99%

Comparison between the Significant of Antenatal Pelvic Floor Exercises and Non-Intervention in Preventing Urinary Incontinence: A Systematic Literature Review

Alfarra¹

2017

J Nov Physiother

View full text Add to dashboard Cite

IntroductionUrinary incontinence as defined by the International Continence Society is the complain of any involuntary leakage of urine [1][2][3]. The world Health Organization (WHO) has classified UI as one of the ten major health problems of present times among women [4]. Causes of UI can be divided into: dysfunction of the bladder or urethra, and neurological or gynecological causes. Gynecological components include: the weakening of pelvic floor muscles, gynecological and obstetrical operations and pelvic organ prolapse [5]. Existing evidence indicates that both natural delivery, as well as the pregnancy itself [6] has a prominent impact on the functioning of pelvic floor muscles and the occurrence of urinary incontinence. SUI occurs when intra-vesical pressure exceeds urethral closure pressure in the absence of a detrusor contraction. SUI may be due to bladder neck hyper-mobility or poor urethral closure pressure [7]. The pelvic floor muscles (PFM) function to elevate the bladder, preventing descent of the bladder neck during rises in intra-abdominal pressure and to occlude the urethra. The theoretical basis for physical therapy to treat SUI is to improve PFM function by increasing strength, coordination, speed and endurance [5] in order to maintain an elevated position of bladder neck during raised intra-abdominal pressure with adequate urethral closure force [8]. Since 1992, conservative management of SUI has been promoted by the US Department of Health and Human Services (AHCPER) as first -line treatment for SUI for its efficacy, low cost and low risk [9].According to Boyle [10], up to a third of women have urinary incontinence while about a 10 th of them have stool incontinence after delivery. Urinary incontinence is a major clinical problem with profound effects on the quality of life and day-to-day activities of the affected women. It's physically debilitating and socially incapacitating, with loss of self-confidence, helplessness, depression and anxiety all related to its occurrence. Affected women suffer social stigma and are withdrawn socially. As a result their productivity is significantly reduced and may lose interest in life.Chiarelli P [11] indicates that the prevalence of urinary incontinence among women increases during young adult life: a study with over 40000 women estimated a prevalence of 12.8% in women aged 18-22 years, 36.1% in women aged 40-49, and 35% in women aged 70-74 years.The severity of urinary incontinence varies in severity ranging from mild, moderate to severe forms. These levels of incontinence require different approaches in management in terms of duration and intensity. AbstractBackground: Urinary incontinence is a common symptom observed in modern times, which may affect 7-37% of women aged 20-39 and 9-39% after the age of 60. Pregnancy and natural delivery are important risk factors increasing the likelihood of incontinence. Conservative intervention such as pelvic floor muscle training (PFMT) is superior in preventing and treating urinary incontinence.

show abstract

“…Epidemiologic data report considerable differences also regarding prevalence of lubrication and arousal dysfunction (12-41.9%), orgasmic dysfunction (11-72%) and genito-pelvic pain (1-68%) (8,(11)(12)(13)(14)(15)(16). Sexual function in women results from a complex neurovascular process that is controlled by psychological, psychosocial, inter-personal and endocrine inputs, consequently the aetiology and risk factors of FSD can be due to one or more systems and there is no consensus on the contribution of each of them (17). Already known risk factors for FSD are of biological, psychological and socio-cultural origin and their role on the different aspects of sexual disorders is often unclear.…”

Section: Introductionmentioning

confidence: 99%

Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women

Borghi

Dell’Atti²

2017

Arch Ital Urol Androl

View full text Add to dashboard Cite

Female Sexual Disorders (FSD) include a complex, multidimensional, individual experience that can change as an individual age, suggesting that these problems are caused by multiple factors including psychosocial factors, personal relationships, pathologic changes caused by diseases, and pharmacologic influences. Menopause is an important time for middle aged women and postmenopausal physiological changes could have a significant role in the development of FSD. Few is still known about their correct definition and treatment. Their incidence, prevalence and risk factors are difficult to define because of a high level of overlap in the experience of problems with desire, arousal, and orgasm. Little evidences are known about the best therapeutic approach, and both non-pharmacological and pharmacological treatment options have been described. Among these, phosphodiesterase type 5 inhibitors could be an effective option for many subtypes of female sexual disorders, with an improvement in different aspects of sexual function, such as desire, arousal, orgasm and sexual satisfaction. In this paper authors reviewed what is already known about the use of these vasoactive agents, particularly tadalafil, as a treatment option for female sexual disturbances.KEY WORDS: Female Sexual Disorders; Phosphodiesterase type 5 inhibitors; Tadalafil; Women. changes could have a significant role in the development of FSD. Nevertheless, despite an increased awareness of its pathophysiology, studies didn't find an agreement on what is the best therapeutic approach and currently there are no drugs approved for most of the complaints (3). Phosphodiesterase type 5 inhibitors (PDE5i) have been widely used for the treatment of male sexual dysfunction (4). In this paper authors review the current literature on FSD and analyse PDE5i, particularly tadalafil, as a treatment option for this health issue. CURRENT KNOWLEDGE OF FEMALE SEXUAL DYSFUNCTIONThe concept of FSD comprises a wide range of disorders, whose definition has undergone numerous changes and classifications in the past. Different definitions included hypoactive sexual desire, impaired subjective or physical genital arousal, sexual pain and inability to achieve orgasm, which are multidimensional issues, often coexisting. The most frequently used classification systems are the International Classification of Diseases, 10 th Edition (ICD-10) by the WHO (5) and the Diagnostic and Statistical Manual of Mental Disorder, Fifth Edition (DSM-5) by the American Psychiatric Association (6). The former subdivides the disorders as organic or non organic. For female, organic disorders include vaginismus and dyspareunia of organic aetiology. Non organic female sexual dysfunctions include lack of sexual desire, sexual aversion or lack of sexual enjoyment, failure of genital response, orgasmic dysfunction, non-organic vaginismus, non-organic dyspareunia, excessive sexual drive and two non-specific codes. These causes are summarized in Table 1. The latter, introduced in 2013, defines the most prevalent ...

show abstract

Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges

Cited by 80 publications

References 70 publications

Comparison of the Effects of Elaeagnus angustifolia Flower Capsule and Sildenafil Citrate Tablet on Anxiety Resulting From Sexual Dysfunction in Women Referring to the Selected Clinics of Shiraz University of Medical Sciences

Comparison of the Effects of Elaeagnus angustifolia Flower Capsule and Sildenafil Citrate Tablet on Anxiety Resulting From Sexual Dysfunction in Women Referring to the Selected Clinics of Shiraz University of Medical Sciences

Comparison between the Significant of Antenatal Pelvic Floor Exercises and Non-Intervention in Preventing Urinary Incontinence: A Systematic Literature Review

Tadalafil once daily: Narrative review of a treatment option for female sexual dysfunctions (FSD) in midlife and older women

Contact Info

Product

Resources

About